“CLINICAL-PATOGENETIC RATIONALE FOR THE USE OF GLYCOSAMINOGLYCANS IN THE TREATMENT OF PATIENTS WITH GLOMERULONEPHRITIS” (2023) Art of Medicine, 28(4), pp. 88–93. doi:10.21802/artm.2023.4.28.88.